Actively Recruiting
Trastuzumab Deruxtecan in Advanced Breast Cancer
Led by Wenjin Yin · Updated on 2025-11-18
118
Participants Needed
1
Research Sites
179 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
CONDITIONS
Official Title
Trastuzumab Deruxtecan in Advanced Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 and older
- Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan
- ECOG 0-1
You will not qualify if you...
- During pregnancy and lactation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China, 200127
Actively Recruiting
Research Team
W
Wenjin Yin, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here